1. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy.
- Author
-
Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, van Kessel AG, Wijmenga C, Ophoff RA, and Veltman JA
- Subjects
- Adult, Chromosomes, Human, Pair 7, Female, Humans, In Situ Hybridization, Fluorescence methods, Male, Middle Aged, Sequence Analysis, Epilepsy genetics, Gene Dosage genetics, Genetic Predisposition to Disease, Membrane Proteins genetics, Nerve Tissue Proteins genetics, Polymorphism, Single Nucleotide, Schizophrenia genetics
- Abstract
A homozygous mutation of the CNTNAP2 gene has been associated with a syndrome of focal epilepsy, mental retardation, language regression and other neuropsychiatric problems in children of the Old Order Amish community. Here we report genomic rearrangements resulting in haploinsufficiency of the CNTNAP2 gene in association with epilepsy and schizophrenia. Genomic deletions of varying sizes affecting the CNTNAP2 gene were identified in three non-related Caucasian patients. In contrast, we did not observe any dosage variation for this gene in 512 healthy controls. Moreover, this genomic region has not been identified as showing large-scale copy number variation. Our data thus confirm an association of CNTNAP2 to epilepsy outside the Old Order Amish population and suggest that dosage alteration of this gene may lead to a complex phenotype of schizophrenia, epilepsy and cognitive impairment.
- Published
- 2008
- Full Text
- View/download PDF